Revive TherapeuticsRVVTF -9.68% EV-to-FCF is -50.64 as of Jul. 11, 2026. The stock has 2 warning signs investors should review. Among 562 Drug Manufacturers companies, Revive Therapeutics ranks worse than 177935.77% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Revive Therapeutics's Enterprise Value is $8.36 Mil.
Revive Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.17 Mil. Therefore, Revive Therapeutics's EV-to-FCF for today is -50.64.
The historical rank and industry rank for Revive Therapeutics's EV-to-FCF or its related term are showing as below:
RVVTF'
s EV-to-FCF Range Over the Past 10 Years
Min: -64.86 Med: 0 Max: 0
Current: -50.64
RVVTF's EV-to-FCF is ranked worse than 100% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.765
vs RVVTF: -50.64
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Revive Therapeutics's PE Ratio (TTM) for today is calculated as:
Revive Therapeutics's share price for today is $0.021.
Revive Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Revive Therapeutics EV-to-FCF Related Terms
Revive Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Revive Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Revive Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revive Therapeutics EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Revive Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Revive Therapeutics's EV-to-FCF falls into.
Revive Therapeutics's current Enterprise Value is $8.36 Mil.
Revive Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revive Therapeutics (RVVTF) has a EV-to-FCF of -50.64 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Revive Therapeutics and its competitors. According to the industry distribution chart, Revive Therapeutics ranks #999999 out of 562 companies in the Drug Manufacturers industry.
Is Revive Therapeutics' EV-to-FCF too high?
Revive Therapeutics' current EV-to-FCF is -50.64. Based on the distribution chart, Revive Therapeutics ranks #999999 out of 562 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Revive Therapeutics' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Revive Therapeutics ranks #999999 out of 562 companies for EV-to-FCF. This places Revive Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 20.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.77, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Revive Therapeutics and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revive Therapeutics's current EV-to-FCF is -50.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revive Therapeutics stock overvalued right now?
Revive Therapeutics (RVVTF) has a current EV-to-FCF of -50.64. The current EV-to-FCF is -50.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Revive Therapeutics (RVVTF), the current EV-to-FCF is -50.64 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. The company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVVTF has been successfully added to your 